Almirall SA : Q4 earnings preview. We expect the soft momentum to remain
>Sales to decline by 8% y-o-y due to a hard comp - The company is due to publish its Q4 2023 results on 19 February before the market opens. We expect total sales to decline 8% y-o-y to € 212m (vs +4% in Q3 +8% in Q2 and +2% in Q1). The figure is impacted by a strong comparison basis in Q4 2022, and the exit from the perimeter of Motilex which was perpetually licensed to Teofarma at the end of Q4 2022. At the EBITDA level, we expect a decline of -33% to € 35m, explain...Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.